Biotech | December 11, 2021
Alembic acquires stake in RIGlmmune
The company is focused on the development of novel treatments for RNA viruses
The company is focused on the development of novel treatments for RNA viruses
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Owkin builds best-in-class predictive biomedical AI models and robust data sets
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Subscribe To Our Newsletter & Stay Updated
